Results 151 to 160 of about 5,314 (201)

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. [PDF]

BMJ Open Gastroenterol
Mustafa A, Davlidova S, Abidi SH, Begimbetova D, Heimer R, Vermund SH, Ali S.   +6 more
europepmc   +1 more source

Characteristics of a Chinese Cohort of Patients with Chronic Hepatitis C Infection (2019-2023) and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir Treatment. [PDF]

J Clin Transl Hepatol
Xiong H, Pan S, Zhou C, Shi H, Xie Y, Guo J.   +5 more
europepmc   +1 more source

Epidemiological characteristics, genotype patterns, and treatment outcomes in chronic hepatitis C patients receiving direct-acting antivirals: a cohort study from Istanbul, Türkiye. [PDF]

BMC Infect Dis
Karaman Kamalı S, Senoglu S, Kamalı S, Ozdemir YE, Kart Yasar K.   +4 more
europepmc   +1 more source

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye. [PDF]

Viruses
Binay UD, Karakeçili F, Aygen B, Kılınç Toker A, Çelik İ, Demirtürk N, Şimşek Bozok T, Dursun L, Akgül F, Çınar G, Günal Ö, Asan A, Arslan E, Yılmaz Karadağ F, Barkay O, Akdemir İ, Şimşek F, Türkoğlu Yılmaz E, Eğilmez ZR, Tekin S, The Viral Hepatitis Study Group Of The Turkish Society Of Clinical Microbiology And Infectious Diseases Klimik.   +20 more
europepmc   +1 more source

Medicaid and Medicare Utilization of Direct-Acting Antiviral Medications for Patients With Hepatitis C. [PDF]

Gastro Hep Adv
Ying X, Zhao A, Ng N, Rosenblatt R, Lucero C, Jesudian AB.   +5 more
europepmc   +1 more source

Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study. [PDF]

Pathogens
Pugliese N, Conti F, Rosato V, Gallo P, Gitto S, Riglietta M, Frigerio F, Perrone V, Veronesi C, Cappuccilli M, Degli Esposti L, Mangia A, Kondili LA.   +12 more
europepmc   +1 more source

Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis. [PDF]

BMJ Public Health
Nisingizwe MP, Tadrous M, Janjua NZ, Bansback N, Hedt-Gauthier B, Suda KJ, Law MR.   +6 more
europepmc   +1 more source

HBV, HCV, and HDV Triple-Infection-A Therapeutic Challenge. [PDF]

Diseases
Balta AAS, Ignat MD, Barbu RE, Baroiu L, Moroianu LA, Lutenco V, Bulza V, Patriciu M, Dumitru C, Debita M.   +9 more
europepmc   +1 more source

Sustained Virological Response After Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Individuals With and Without Decompensated Liver Cirrhosis: A One-Year Follow-Up Study. [PDF]

Cureus
Shailja, Radera S, Rungta S, Jeet A, Jain A.   +4 more
europepmc   +1 more source

Direct-Acting Antiviral Treatment Failure and Retreatment Strategies Following Hepatitis C-Positive Solid Organ Transplantation in Hepatitis C-Negative Recipients: A Multicenter Case Series. [PDF]

Transpl Infect Dis
Carver AB, Özoral C, Lange M, Mattise A, Whelchel K, Perri R.   +5 more
europepmc   +1 more source